YMAB Live signals | Maximize Profits with Getagraph.com

BUY 157651 min ago

@ $15.77

Issued: 14 Feb 2024 @ 14:20

Return: -23.27%

Previous signal: Feb 13 - 15:31

Previous signal: Sell

Return: 6.45 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	776 989
Average Volume	367 353
Market Cap	530.98M
EPS	$0 ( 2024-05-13 )
Next earnings date	( $-0.100 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-24.69
ATR14	$0.0190 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-30	Kruse Bo	Sell	28 629	Employee Stock Option (right to buy)
2024-05-31	Kruse Bo	Buy	31 371	Common Stock
2024-05-31	Kruse Bo	Sell	31 371	Employee Stock Option (right to buy)
2024-05-30	Kruse Bo	Buy	28 629	Common Stock
2024-05-31	Kruse Bo	Sell	31 371	Common Stock

INSIDER POWER
67.51
Last 98 transactions
Buy: 3 515 211 \| Sell: 509 644

Volume Correlation

Long: 0.14 (neutral)

Short: -0.65 (weak negative)

Signal:(51.605) Neutral

Y-mAbs Therapeutics, Inc Correlation

10 Most Positive Correlations
HQY	0.922
VERA	0.864
TIL	0.858
ADP	0.855
FSEA	0.855
PYXS	0.854
BHFAL	0.838
SWTX	0.835
MAR	0.831
INBK	0.83

10 Most Negative Correlations
WABC	-0.935
SGML	-0.921
NBTB	-0.915
HAFC	-0.915
COLB	-0.913
VNET	-0.909
BSGM	-0.908
TCBK	-0.907
BANR	-0.904
RNRG	-0.9

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Y-mAbs Therapeutics, Inc Correlation - Currency/Commodity

-0.07
( neutral )

-0.03
( neutral )

0.00
( neutral )

-0.10
( neutral )

0.06
( neutral )

Y-mAbs Therapeutics, Inc Financials

Annual	2023
Revenue:	$84.82M
Gross Profit:	$73.40M (86.54 %)
EPS:	$-0.490

FY	2023
Revenue:	$84.82M
Gross Profit:	$73.40M (86.54 %)
EPS:	$-0.490

FY	2022
Revenue:	$65.27M
Gross Profit:	$57.70M (88.41 %)
EPS:	$-2.20

FY	2021
Revenue:	$34.90M
Gross Profit:	$32.38M (92.80 %)
EPS:	$-1.378

Financial Reports:

No articles found.

Y-mAbs Therapeutics, Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Y-mAbs Therapeutics, Inc

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.